ClinicalTrials.gg
CompletedNCT00567385Updated Feb 28, 2017

Liquid Somatropin Formulation in Children With Growth Hormone Deficiency

A Phase 4 interventional study of somatropin in Growth Hormone Disorder and Growth Hormone Deficiency in Children, sponsored by Novo Nordisk A/S. Completed at 1 site in Turkey. Open to participants aged 3 Years to 18 Years. Per ClinicalTrials.gov, last updated 2017-02-28.

Sponsored by Novo Nordisk A/S · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 4 years 8 months after the study started (first participant enrolled Mar 2003, registered Nov 2007).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
176
Allocation
Non-randomized
Ages
3 Years to 18 Years
Sex
All
01

Study summary

This trial is conducted in Europe. The aim of this trial is to evaluate the acceptance of the new liquid growth hormone formulation, somatropin, in children with growth hormone deficiency.

02

Conditions studied

  • Growth Hormone Disorder
  • Growth Hormone Deficiency in Children
03

In context

Lead sponsor

Novo Nordisk A/S is the lead sponsor of 1,411 studies on the registry; 108 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
3 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Growth failure due to growth hormone insufficiency (GHD)
  • Turner syndrome: established diagnosis according to sex chromosome analysis, or
  • Growth retardation in children with chronic renal disorders

Exclusion criteria

Exclusion Criteria:

  • Pregnancy
  • Breast feeding women
  • Suspected or know allergy to trial product
  • Participating in any other trial involving other products within the last 3 months
  • Previous participation in the trial
  • Other daily injection therapy (non-growth hormone, e.g insulin-therapy)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
176 participants (actual)

Interventions

06

What researchers measure

Primary outcomes

  1. Assessment of acceptance

    Time frame: after 12 weeks of treatment

Secondary outcomes

  1. Safety

  2. Adverse Events (AE)

  3. Compliance

07

Study locations

1 site
  • Novo Nordisk Investigational Site
    Altunizade-Istanbul, 34662, Turkey
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2003 to primary completion in Mar 2004, 12 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 30, 2007
First posted
Dec 4, 2007
StartActual
Mar 10, 2003
Primary completionActual
Mar 22, 2004
CompletionActual
Mar 22, 2004
Last update
Feb 28, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 28, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00567385
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Dec 4, 2007
Start date
Mar 10, 2003
Primary completion
Mar 22, 2004
Completion
Mar 22, 2004
Last update
Feb 28, 2017

Study contacts

Global Clinical Registry (GCR, 1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Human Growth Hormone

Start the discussion